focus -WSS

focus

author：comprehensive 2025-10-03 00:04:23 - browse：73

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readout Newsletter: Zepbound, Valneva's vaccine, and more

explore

WSS

Weight loss drugs should be covered by insurers, AMA says

Using force crossed my mind when examining a defiant young patient

UnitedHealth sued over use of algorithm in Medicare Advantage plans

After decades in use, heart stents finally beat placebo

What health policies could hitch a ride on a spending bill?

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

focus

focus

focus

Affirmative action in medical school literally saved lives

Color Health wants to make cancer screenings convenient

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

As demand for Covid shots wanes, Moderna seeks its next success

What health policies could hitch a ride on a spending bill?

The cancer drug shortage isn’t new — and neither are the solutions

First transplant of an entire human eye performed

leisure time

'Vaccine

Today's health inequities arise from racist U.S. history, say experts

Using force crossed my mind when examining a defiant young patient

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

What health policies could hitch a ride on a spending bill?

STAT Madness 2024: Meet the contenders

hotspot

explore

Wikipedia

focus